// App-Quantinova.ai

2582 : Updated efficacy and safety results from the phase I study of intermittent dosing of the dual MEK/RAF inhibitor, RO5126766 in patients (pts) with RAS/RAF mutated advanced solid tumours.

Researchers

Presenter

  • Samuel John Harris

Principal Investigators

  • Maria Jose de Miguel Luken

  • Desamparados Roda Perez

  • Raquel Perez Lopez

  • Mona Parmar

  • Vasanthi Prathapan

  • Hasina Hassam

  • Alison Joanne Turner

  • Sonia Serrano Fandos

  • Emma Hall

  • Holly Tovey

  • Nina Tunariu

  • Juanita Suzanne Lopez

  • Timothy Anthony Yap

  • Johann S. De Bono

  • Udai Banerji

Medical Centers

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Institute of Cancer Research Clinical Trials and Statistics Unit, Sutton, United Kingdom

  • Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • GTPase Nras

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • RO5126766

Outcome

  • Unknown

Study Design

  • Pharmacodynamics

Phase

  • I

Study Id's

  • NCT02407509

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved